074430 — Aminologics Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩131bn
- KR₩104bn
- KR₩21bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 18,980 | 17,651 | 22,849 | 27,337 | 20,887 |
Cost of Revenue | |||||
Gross Profit | 3,293 | 6,986 | 9,135 | 12,808 | 7,776 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 19,741 | 15,175 | 20,278 | 33,820 | 19,425 |
Operating Profit | -761 | 2,476 | 2,571 | -6,483 | 1,462 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1,201 | 2,074 | 3,704 | -6,281 | 2,291 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,201 | 2,140 | 5,360 | -7,282 | 2,436 |
Net Income Before Extraordinary Items | |||||
Net Income | -1,201 | 2,140 | 5,360 | -7,282 | 2,436 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -1,201 | 2,140 | 5,360 | -7,282 | 2,436 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -13.7 | 24.4 | 72.4 | 17.1 | 27.7 |
Dividends per Share |